Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03SKD
|
|||
| Former ID |
DAP000283
|
|||
| Drug Name |
Oxycodone
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Pain [ICD-11: MG30-MG3Z] | Approved | [1], [2] | |
| Back pain [ICD-11: ME84.Z] | Phase 3 | [3] | ||
| Therapeutic Class |
Analgesics
|
|||
| Company |
Watson Laboratories
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H21NO4
|
|||
| Canonical SMILES |
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O
|
|||
| InChI |
1S/C18H21NO4/c1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10/h3-4,13,16,21H,5-9H2,1-2H3/t13-,16+,17+,18-/m1/s1
|
|||
| InChIKey |
BRUQQQPBMZOVGD-XFKAJCMBSA-N
|
|||
| CAS Number |
CAS 76-42-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
10218, 81987, 7980232, 11039373, 14825887, 14923583, 16697449, 39317907, 46508908, 47207011, 48416366, 49993158, 50887162, 56464157, 85242752, 92714668, 103189261, 104133805, 117497014, 126629457, 127559039, 134222776, 134337597, 135269853, 137001259, 139157519, 152101652, 160849697, 160963843, 162224649, 175266292, 178103671, 179116835, 184548425, 223656812, 223800482, 226395100
|
|||
| ChEBI ID |
CHEBI:7852
|
|||
| SuperDrug ATC ID |
N02AA05
|
|||
| SuperDrug CAS ID |
cas=000076426
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Opioid receptor delta (OPRD1) | Target Info | Agonist | [4] |
| Opioid receptor mu (MOP) | Target Info | Modulator | [5] | |
| KEGG Pathway | cGMP-PKG signaling pathway | |||
| Sphingolipid signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Estrogen signaling pathway | ||||
| Morphine addiction | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Enkephalin release | ||||
| Opioid proenkephalin pathway | ||||
| Opioid proopiomelanocortin pathway | ||||
| Pathway Interaction Database | IL4-mediated signaling events | |||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| TCR Signaling Pathway | ||||
| Opioid Signalling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7093). | |||
| REF 2 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 085910. | |||
| REF 3 | ClinicalTrials.gov (NCT01427283) A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain. U.S. National Institutes of Health. | |||
| REF 4 | Oxycodone: a pharmacological and clinical review. Clin Transl Oncol. 2007 May;9(5):298-307. | |||
| REF 5 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.